IGF‑1 DES is a truncated IGF‑1 peptide that community members use primarily for muscle growth and localized hypertrophy, despite lacking any FDA‑approved indication. Users most often administer 100 µg per day, while a clinician source recommends 75 µg IM daily; schedules and cycling are rarely specified. The main caveat is that the off‑label evidence base is thin, with exploratory studies offering little published data. Injection‑site reactions and other common side‑effect buckets have not emerged as consistent reports in the limited community feedback.
Data last updated
Measured on 5 of 6 axes
Evidence shape
The only human data for IGF‑1 DES are limited, coming from a single exploratory study used for diagnostic and mechanistic purposes. Across the peptide’s record there are two mapped indications—a thin, single‑trial human study and a pre‑clinical, animal‑only line of research—without any completed or registered trials to substantiate broader efficacy. In short, the evidence base is sparse, unblinded and confined to early‑stage investigations.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How IGF-1 DES is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
According to the available data, no completed trial has been identified for this tier, so dosing cannot be reliably extracted.
The clinician tier reports a typical dose of 75 mcg administered intramuscularly, with no specified frequency or cycling, based on a single report.
Community users report a single subcutaneous injection of 100 mcg of IGF‑1 DES, with no consistent frequency or cycling pattern reported.